You have 9 free searches left this month | to do more
Showing 1 - 25 of
755 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
D
Completed
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-03-15
Mar 15, 2022
C
Completed
  • Rheumatoid Arthritis
  • CT-P10
  • +2 more
  • (no location specified)
2021-11-18
Nov 18, 2021
C
Completed
  • Follicular Lymphoma
  • CT-P10
  • Rituxan
  • Seoul, Korea, Republic of
    Severance Hospital
2021-03-16
Mar 16, 2021
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Tampa, Florida
  • +3 more
2022-03-26
Mar 26, 2022
E
Recruiting
  • Cutaneous Melanoma, Stage III
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
2021-06-17
Jun 17, 2021
G
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Washington, District of Columbia
  • +1 more
2022-03-14
Mar 14, 2022
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-02
Feb 2, 2022
L
Withdrawn
  • Follicular Lymphoma
  • +2 more
  • MTD of Velcade, Nipent and Rituxan established in Part 1
  • Shreveport, Louisiana
    LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Ce
2020-08-28
Aug 28, 2020
N
Recruiting
  • Graft Vs Host Disease
  • Atlanta, Georgia
    Northside Hospital
2022-04-04
Apr 4, 2022
M
Completed
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-03-03
Mar 3, 2022
S
Recruiting
  • Mature B-Cell Lymphoma
  • San Diego, California
  • +3 more
2022-01-19
Jan 19, 2022
A
Terminated
  • Chronic Lymphocytic Leukemia
  • Peripheral T-cell Lymphoma
  • 20 mg/kg TRU-016 + Rituximab
  • +5 more
  • Augusta, Georgia
  • +7 more
2021-05-18
May 18, 2021
U
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • CLL
  • La Jolla, California
    University of California, San Diego
2021-09-02
Sep 2, 2021
N
Recruiting
  • Lymphomatoid Granulomatosis
  • +3 more
  • Interferon
  • Rituxan and EPOCH
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-31
Mar 31, 2022
D
Recruiting
  • Follicular Lymphoma
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2022-03-14
Mar 14, 2022
M
Not yet recruiting
  • CLL
  • (no location specified)
2022-02-08
Feb 8, 2022
K
Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
2021-02-20
Feb 20, 2021
W
Recruiting
  • Mantle Cell Lymphoma
  • New York, New York
    Weill Cornell Medicine
2021-10-29
Oct 29, 2021
D
Recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
2022-02-02
Feb 2, 2022
S
Terminated
  • Follicular Lymphoma
  • Sun City, Arizona
  • +4 more
2021-09-06
Sep 6, 2021
J
Recruiting
  • Follicular Lymphoma
  • Miami, Florida
    University of Miami
2022-02-22
Feb 22, 2022
J
Recruiting
  • IgM MGUS
  • +2 more
  • Boston, Massachusetts
  • +1 more
2022-02-16
Feb 16, 2022
A
Completed
  • Lymphoma
  • Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
  • Rochester, Minnesota
    Mayo Clinic
2020-01-06
Jan 6, 2020
S
Recruiting
  • AML
  • +3 more
  • CD123-CAR T
  • +4 more
  • Memphis, Tennessee
    St. Jude Children's Hospital
2021-08-06
Aug 6, 2021
D
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021